[go: up one dir, main page]

MX2009009997A - Preparacion de la capsula de tamibarotene. - Google Patents

Preparacion de la capsula de tamibarotene.

Info

Publication number
MX2009009997A
MX2009009997A MX2009009997A MX2009009997A MX2009009997A MX 2009009997 A MX2009009997 A MX 2009009997A MX 2009009997 A MX2009009997 A MX 2009009997A MX 2009009997 A MX2009009997 A MX 2009009997A MX 2009009997 A MX2009009997 A MX 2009009997A
Authority
MX
Mexico
Prior art keywords
tamibarotene
capsule
preparation
preferable
base
Prior art date
Application number
MX2009009997A
Other languages
English (en)
Inventor
Hsiao Ekimoto
Original Assignee
Tmrc Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tmrc Co Ltd filed Critical Tmrc Co Ltd
Publication of MX2009009997A publication Critical patent/MX2009009997A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una forma práctica de preparar Tamibarotene y la dosis de este, la cual exhibe una alta absorción en el cuerpo, con una toxicidad minimizada, y siendo segura y estable, sin riesgo alguno de contaminación. Se proporciona una preparación de la cápsula de Tamibarotene encapsulando una composición que incluye un componente oleaginoso como base y Tamibarotene como un ingrediente activo disuelto en la base. Es preferible que el componente oleaginoso sea un ester de ácido graso de propilen glicol o polietilen glicoles. También, es preferible que la preparación de la cápsula de Tamibarotene incluya 0.1 a 50 mg/mL de Tamibarotene, en base al componente oleaginoso.
MX2009009997A 2007-03-30 2008-03-28 Preparacion de la capsula de tamibarotene. MX2009009997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007092604 2007-03-30
PCT/JP2008/056073 WO2008120711A1 (ja) 2007-03-30 2008-03-28 タミバロテンカプセル剤

Publications (1)

Publication Number Publication Date
MX2009009997A true MX2009009997A (es) 2009-12-08

Family

ID=39808291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009997A MX2009009997A (es) 2007-03-30 2008-03-28 Preparacion de la capsula de tamibarotene.

Country Status (10)

Country Link
US (1) US8252837B2 (es)
EP (1) EP2143428B1 (es)
JP (1) JP5539713B2 (es)
KR (1) KR20100016048A (es)
CN (1) CN101641091B (es)
CA (1) CA2681712C (es)
ES (1) ES2559420T3 (es)
MX (1) MX2009009997A (es)
NZ (1) NZ580209A (es)
WO (1) WO2008120711A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829044B (zh) * 2009-03-13 2013-02-20 北京本草天源药物研究院 一种他米巴罗汀固体制剂及其制备方法
CN101708168B (zh) * 2009-12-02 2011-07-20 深圳万乐药业有限公司 一种他米巴罗汀分散片的制备方法
JP2013199458A (ja) * 2012-03-26 2013-10-03 Tmrc Co Ltd カプセル製剤
MX365321B (es) 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
CA2906800A1 (en) * 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing the effects of aging
WO2015045037A1 (ja) * 2013-09-25 2015-04-02 テムリック株式会社 カプセル製剤
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
CN104162167A (zh) * 2014-07-18 2014-11-26 山东大学 他米巴罗汀环糊精或环糊精衍生物包合物及其制备方法
IL309066A (en) 2015-03-31 2024-02-01 Syros Pharmaceuticals Inc Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
ES2898676T3 (es) * 2015-11-25 2022-03-08 Io Therapeutics Inc Agonistas selectivos de rar-alfa resistentes a CYP26 en el tratamiento del cáncer
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
BR112018070547A2 (pt) 2016-04-08 2019-02-12 Syros Pharmaceuticals, Inc. agonistas de rara para o tratamento de aml e mds
US20220185767A1 (en) * 2019-04-02 2022-06-16 Transgenex Nanobiotech, Inc. Novel ternary molecular complex of tamibarotene for cancer stem cells treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316917A (en) * 1980-04-21 1982-02-23 Hoffman-La Roche Inc. Stable carotenoid solutions
JPS6176440A (ja) 1984-09-19 1986-04-18 Koichi Shiyudo 安息香酸誘導体
US4808631A (en) * 1986-11-07 1989-02-28 Hoffmann-La Roche Inc. Aromatic acid derivatives
DK0478787T3 (da) 1990-03-20 1995-02-20 Shionogi & Co Ny fremgangsmåde til fremstilling af et benzoesyrederivat
JPH0525037A (ja) * 1991-07-01 1993-02-02 Upjohn Co:The 経口投与酵素感受性腸溶製剤
JPH0717854A (ja) * 1993-04-05 1995-01-20 Koichi Shudo 抗骨疾患剤
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
JPH07196478A (ja) 1993-12-30 1995-08-01 Hajime Sugii 安全性の高い食品及び医薬品用ソフトカプセル
JPH10251144A (ja) * 1997-03-11 1998-09-22 Iyaku Bunshi Sekkei Kenkyusho:Kk インターロイキン−６産生阻害剤
ES2349461T3 (es) 2000-09-01 2011-01-03 Toko Pharmaceutical Ind. Co. Ltd Procedimiento de producción de cristales de un derivado de acido benzoico.
JP5105705B2 (ja) * 2002-05-09 2012-12-26 中外製薬株式会社 光安定化軟カプセル剤
CN1660064B (zh) 2004-12-28 2010-09-29 中山大学 那格列奈自乳化释药系统

Also Published As

Publication number Publication date
AU2008233631A1 (en) 2008-10-09
CA2681712A1 (en) 2008-10-09
EP2143428B1 (en) 2015-11-04
CA2681712C (en) 2013-05-07
US20100048708A1 (en) 2010-02-25
EP2143428A1 (en) 2010-01-13
JPWO2008120711A1 (ja) 2010-07-15
NZ580209A (en) 2011-11-25
JP5539713B2 (ja) 2014-07-02
WO2008120711A1 (ja) 2008-10-09
US8252837B2 (en) 2012-08-28
CN101641091B (zh) 2012-09-19
ES2559420T3 (es) 2016-02-12
HK1137367A1 (en) 2010-07-30
KR20100016048A (ko) 2010-02-12
CN101641091A (zh) 2010-02-03
EP2143428A4 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
MX2009009997A (es) Preparacion de la capsula de tamibarotene.
AR076686A1 (es) Compuesto anticancerigeno y composicion farmaceutica que lo contiene
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
MX388787B (es) El uso de amisulpride como un anti-emético.
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
ECSP10010395A (es) Formulacion de capsula
PE20120322A1 (es) Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
AR047928A1 (es) Derivados de tetrahidropiridoindol
PE20080523A1 (es) Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
MX338324B (es) Composiciones y metodos para reducir trigliceridos sin elevar los niveles de ldl-c en un sujeto en terapia de estatina concomitante.
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR083591A1 (es) Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona
BR112019023981A2 (pt) injeção de octreotida
AR084235A1 (es) Composiciones farmaceuticas que comprenden alisporivir
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
RU2013137782A (ru) Водный ионный раствор, содержащий морскую воду, по меньшей мере одно соединение, изначально не смешивающееся с морской водой
GT200700020A (es) Compuestos y derivados de dibencilamina
TW200726460A (en) Anti-fatigue composition
NI201200196A (es) Agentes terapéuticos 976

Legal Events

Date Code Title Description
FG Grant or registration